^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Rituxan (rituximab)

i
Other names: R-105, RG-105, RO-45 2294, IDEC 102, RG105, IDEC-C2B8, RO-452294, R 105, RG 105, IDEC-102, R105, IDEC-C2B8 anti-CD20, RO 45-2294, Ro 45-2294, RO452294, RO 452294, IDEC102, IDEC C2BB
Company:
Biogen, Roche, Zenyaku Holdings
Drug class:
CD20 inhibitor
Related drugs:
18h
New P2 trial
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
2d
Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients. (PubMed, Hematol Oncol)
We analyzed 125 patients with the following characteristics: median age, 61 years (55; 67), advanced-stage disease, 88.8%; high FLIPI, 49.6%; TMTV, > 510 cm3; B2M, > 3 mg/L (24.8%); and R-CHOP-like treatment, 86.4%...Patients at intermediate and high risk according to the TMTV/B2M score were at high risk of disease progression within 24 months of treatment initiation (HR = 2.45 [95% CI: 1.23-4.85] and HR = 3.75 [95% CI: 1.7-8.2], respectively). This TMTV/B2M score may identify patients with the highest unmet medical needs.
Retrospective data • Journal
|
B2M (Beta-2-microglobulin)
|
Rituxan (rituximab)
3d
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=3, Active, not recruiting, M.D. Anderson Cancer Center | N=24 --> 3 | Trial completion date: Jun 2024 --> Dec 2025
Enrollment change • Trial completion date
|
Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)
3d
Study of Rituximab or Tocilizumab for Patients with Steroid-Dependent Immune-Related Adverse Events (irAEs) (clinicaltrials.gov)
P2, N=30, Recruiting, Columbia University | Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: May 2024 --> Feb 2025
Trial completion date • Trial primary completion date • Adverse events • Checkpoint inhibition • Checkpoint block
|
Rituxan (rituximab) • Actemra IV (tocilizumab)
3d
Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 expression
|
carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
5d
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (clinicaltrials.gov)
P1/2, N=38, Completed, Prof. Dr. Clemens Schmitt | Active, not recruiting --> Completed | Trial primary completion date: Jun 2024 --> Nov 2024
Trial completion • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 positive • BCL6 rearrangement • BCL2 rearrangement
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib • doxorubicin hydrochloride • cyclophosphamide
6d
SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=60, Recruiting, Enterome | Trial completion date: Sep 2029 --> May 2032 | Trial primary completion date: Jun 2025 --> May 2026
Trial completion date • Trial primary completion date • Combination therapy
|
Rituxan (rituximab) • lenalidomide • EO2463
6d
Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003). (PubMed, Br J Haematol)
The complete response rate was 25.0% and 42.9% in the lenalidomide 15- and 20-mg cohorts, respectively. Due to acceptable toxicity and preliminary efficacy, the lenalidomide 20-mg dose was selected for further investigation.
P1 data • Journal • Combination therapy
|
IL2 (Interleukin 2) • ITK (IL2 Inducible T Cell Kinase)
|
Rituxan (rituximab) • lenalidomide • Calquence (acalabrutinib)
7d
Pleural Marginal Zone Lymphoma Masquerading as Metastatic Adenocarcinoma of the Lung. (PubMed, Cureus)
Consequently, she was treated with rituximab for PMZL, with plans to address the adenocarcinoma through stereotactic body radiation therapy (SBRT)...While a direct correlation between chronic inflammation, frequent infectious pathogens, and the development of PMZL has yet to be established, a known association exists between EMZL and pathogens such as Helicobacter pylori in gastric involvement and Chlamydia psittaci in ocular adnexa. This report highlights the difficulties in obtaining a diagnosis for PMZL and examines the various mechanisms that may have contributed to this unusual finding.
Journal • Metastases
|
CD20 (Membrane Spanning 4-Domains A1) • SPN (Sialophorin)
|
Rituxan (rituximab)
7d
New P1 trial • Combination therapy
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq) • methotrexate IV
7d
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR) (clinicaltrials.gov)
P2, N=45, Recruiting, Sanofi | Trial primary completion date: Nov 2024 --> Dec 2025
Trial primary completion date
|
Rituxan (rituximab)
8d
Enrollment closed • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • dexamethasone • bendamustine • Epkinly (epcoritamab-bysp)
8d
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) (clinicaltrials.gov)
P4, N=5, Recruiting, Takeda | Trial completion date: Jun 2027 --> Jul 2028 | Trial primary completion date: Jun 2027 --> Jul 2028
Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • methotrexate IV
9d
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) (clinicaltrials.gov)
P1, N=25, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
Trial completion date • Trial primary completion date • Combination therapy
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide
9d
EA4181: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=360, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14) • CCND1 expression
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Truxima (rituximab-abbs) • Starasid (cytarabine ocfosfate)
10d
BeliVeR: Belimumab in Patients with Chronic Lymphocytic Leukemia (clinicaltrials.gov)
P2, N=120, Active, not recruiting, University Hospital Tuebingen | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
Venclexta (venetoclax) • Rituxan (rituximab)
10d
FIL_V-RBAC: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL (clinicaltrials.gov)
P2, N=141, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Jul 2025 --> Nov 2025
Trial completion date
|
CCND1 (Cyclin D1) • SOX11 (SRY-Box Transcription Factor 11)
|
Chr t(11;14)
|
Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • bendamustine
10d
RENOIR: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (clinicaltrials.gov)
P3, N=128, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Dec 2027 --> Aug 2027
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
LDH elevation
|
Rituxan (rituximab) • lenalidomide
10d
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. (PubMed, J Clin Oncol)
Adverse events were as expected with zanubrutinib; rate of atrial fibrillation was 7.1%. At a median follow-up of 61.2 months, the results supported the initial SEQUOIA findings and suggested that zanubrutinib was a favorable treatment option for untreated patients with CLL/SLL.
Journal
|
IGH (Immunoglobulin Heavy Locus)
|
IGH mutation
|
Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine
11d
Association of PD-L1 Expression with Clinico-Pathological Factors and Treatment Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) from a Tertiary Care Cancer Center in Southern India (ASH 2024)
Treatment included R-CHOP (n=26), R-DA EPOCH (n=2), MTR (n=1), and R-MPV (n=1).26.66% had PD-L1 <1% while 73.33% had PD-L1 ≥1%; 33.33% had PD-L1 <5%, while 66.67% had PD-L1 ≥5%...Limitations include small number of patients, short follow up and inclusion of 2 patients of primary CNS lymphoma, that might have affected the analysis minimally. Further research is essential to standardize the cutoff value and scoring method.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
|
PD-L1 IHC 22C3 pharmDx
|
Rituxan (rituximab)
11d
A Single-Arm, Phase II Study of Acalabrutinib As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Mantle Cell Lymphoma (ASH 2024)
Background : Maintenance therapy with the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib following ibrutinib-containing chemoimmunotherapy with or without high-dose chemotherapy and autologous stem cell rescue (HDT/ASCR) in younger patients (pts) with mantle cell lymphoma (MCL) has demonstrated superior efficacy over standard chemoimmunotherapy with ASCR (Dreyling et al...Concurrent maintenance with rituximab was not used...At 2 years, the PFS rate (95% confidence interval) was 73.5% (35.9, 91.1) in the overall study population, 37.5% (1.1, 80.8) in pts with MRD+, and 88.9% (43.3, 98.4) in pts with MRD-U (MRD based on status at Day 100).Conclusions : Acalabrutinib demonstrated a tolerable safety profile and promising results in maintaining MRD-U, supporting the use of acalabrutinib as maintenance therapy post-HDT/ASCR in pts with MCL. Given the early study closure, the limited sample size, and the need for longer follow-up for PFS, additional investigations may provide further insights into the role of BTKi maintenance in the post-HDT/ASCR setting.
Clinical • P2 data • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
clonoSEQ
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • Calquence (acalabrutinib)
11d
Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses (ASH 2024)
Uni- and multi-variate analyses of clinical variables that may be associated with clinical and MRD outcomes are underway.Conclusions : Bendamustine, rituximab and acalabrutinib front-line therapy for WM is safe and well tolerated in a relatively elderly population with a toxicity profile consistent with the utilized drugs and not greater than that seen with BR and Placebo in the randomized ECHO trial in untreated Mantle Cell Lymphoma. Initial clinical results show that this treatment is associated with a very high proportion of CR + VGPRs as well as MRD negativity.
Clinical
|
TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
TP53 mutation • MYD88 L265P • CXCR4 mutation
|
clonoSEQ
|
Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine
12d
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study. (PubMed, Hematol Oncol)
While 12-month PFS failed to reach statistical significance, subgroup analyses favor Pola-R-CHP. Further research with a wider population, longer follow-up, and screening of advantageous groups are warranted.
Retrospective data • Journal • Real-world evidence • IO biomarker • Real-world
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • PIM1 (Pim-1 Proto-Oncogene) • SOCS1 (Suppressor Of Cytokine Signaling 1)
|
TP53 mutation • PIM1 mutation
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq)
12d
Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China. (PubMed, Sci Rep)
This is an analysis of 127 patients with HIV with Burkitt lymphoma (HIV-BL) and diffuse large B-cell lymphoma (HIV-DLBCL) treated at the Zhongnan Hospital of Wuhan University over a 17-year period during the ART and rituximab era...Current China practice favours the treatment of HIV-BL and HIV-DLBCL similarly to the HIV-negative population with the use of concurrent ART. However, due to the extremely low percentage of patients receiving ART prior to the lymphoma diagnosis, the high percentage of patients with poor performance status, and the advanced stage at diagnosis, the treatment of HIV-related lymphoma remains the major challenge in China.
Retrospective data • Journal
|
CD4 (CD4 Molecule)
|
Rituxan (rituximab)
13d
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (clinicaltrials.gov)
P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • Truxima (rituximab-abbs) • Monjuvi (tafasitamab-cxix)
13d
P+R-ICE: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=65, Active, not recruiting, University of Southampton | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2024 --> May 2026
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
Keytruda (pembrolizumab) • carboplatin • Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • carmustine
14d
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8)
|
CD8 expression • BCL2 translocation
|
Rituxan (rituximab) • cyclophosphamide • vincristine
14d
DEB: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (clinicaltrials.gov)
P3, N=423, Active, not recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Mar 2025 --> Jun 2025
Trial completion date • Combination therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 positive • MYC rearrangement
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
14d
Trial completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • IGH (Immunoglobulin Heavy Locus) • ETV6 (ETS Variant Transcription Factor 6) • CD4 (CD4 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
14d
Interdigitating dendritic cell sarcoma presenting as retroperitoneal mass and obstructive jaundice. An uncommon entity of complex diagnosis. (PubMed, Rev Esp Enferm Dig)
These findings were suggestive of interdigitating dendritic cell sarcoma (IDCS). Systemic chemotherapy with R-CHOP was initiated and after the first 4 cycles of treatment, retroperitoneal adenopathies regressed, with stability of metastatic liver disease.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
Rituxan (rituximab)
15d
AK104-IIT-C-N1-0122: AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC (clinicaltrials.gov)
P2, N=30, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
gemcitabine • Rituxan (rituximab) • albumin-bound paclitaxel • Kaitanni (cadonilimab)
15d
ReCIX: Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov)
P3, N=100, Recruiting, Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)
New P3 trial
|
Rituxan (rituximab)
15d
Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov)
P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: May 2026 --> Feb 2027
Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
15d
Trial completion date • Trial primary completion date • Adverse events • Combination therapy
|
Rituxan (rituximab) • lenalidomide • Epkinly (epcoritamab-bysp)
15d
Trial primary completion date • Combination therapy
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
ALK positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)
15d
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • bendamustine • melphalan
16d
Trial completion date • Trial primary completion date • Adverse events • Combination therapy
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Epkinly (epcoritamab-bysp)
16d
DALY 2-EU: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (clinicaltrials.gov)
P2, N=168, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Jul 2027 --> Jul 2029
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
16d
Trial completion date • Trial primary completion date • Adverse events • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Chr t(11;14) • CCND1 overexpression
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
17d
New trial • Immunomodulating
|
Rituxan (rituximab) • Ocrevus (ocrelizumab)
17d
RiVa: A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma (clinicaltrials.gov)
P1/2, N=26, Completed, University Hospital Southampton NHS Foundation Trust | Active, not recruiting --> Completed | Phase classification: P2a --> P1/2 | Trial completion date: Mar 2024 --> Aug 2024
Trial completion • Phase classification • Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 expression
|
Rituxan (rituximab) • varlilumab (CDX 1127)